SKB103 for Injection in Advanced Solid Tumors

Summary

This is a phase 1/2 clinical study to evaluate the safety and efficacy of SKB103 in participants with advanced solid tumors. The study includes a dose escalation stage, a dose expansion stage, and a indication expansion stage.

Timeline

Start

2026-04-23

Primary completion

2029-12-31

Completion

2030-12-31

Drugs

Indications